VYN202

About Vyne Therapeutics

VYNE Therapeutics is a clinical-stage biopharma company with a mission to solve difficult therapeutic challenges by questioning traditional assumptions. Its core asset is the InhiBET™ platform for developing topical and oral BET inhibitors, with lead candidate VYN201 in Phase 1b for vitiligo. The company's near-term future is defined by a pending all-stock merger with Yarrow Bioscience, announced in December 2025, which will bring a new lead program (YB-101 for Graves' disease) and approximately $200 million in capital, aiming to create a new entity focused on autoimmune endocrinology.

Therapeutic Areas